Litcius/Paper detail

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Sara Y. Tartof, Jeff Slezak, Heidi Fischer, Vennis Hong, Bradley K. Ackerson, Omesh N. Ranasinghe, Timothy B. Frankland, Oluwaseye Ayoola Ogun, Joann M. Zamparo, Sharon Gray, Srinivas Rao Valluri, Kaije Pan, Frederick J. Angulo, Luis Jódar, John M. McLaughlin

2021The Lancet1,281 citationsDOIOpen Access PDF

Topics & Concepts

Coronavirus disease 2019 (COVID-19)MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakRetrospective cohort studyVirologyMEDLINECohortInternal medicineBiologyDiseaseOutbreakBiochemistryInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 Clinical Research Studies
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study | Litcius